Filing Details
- Accession Number:
- 0000874015-20-000150
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-25 19:02:16
- Reporting Period:
- 2020-11-23
- Accepted Time:
- 2020-11-25 19:02:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874015 | Ionis Pharmaceuticals Inc | IONS | Pharmaceutical Preparations (2834) | 330336973 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1074773 | L Elizabeth Hougen | C/O Ionis Pharmaceuticals, Inc. 2855 Gazelle Ct. Carlsbad, CA 92010 | Evp, Finance & Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-11-23 | 13,125 | $39.87 | 45,620 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-11-23 | 13,125 | $50.11 | 32,495 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-11-23 | 5,875 | $39.87 | 38,370 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-11-23 | 5,875 | $50.11 | 32,495 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-11-24 | 4,320 | $39.87 | 36,815 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-11-24 | 4,320 | $50.83 | 32,495 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-11-23 | 13,125 | $0.00 | 0 | $39.87 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-11-23 | 5,875 | $0.00 | 0 | $39.87 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-11-24 | 4,320 | $0.00 | 0 | $39.87 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 31,875 | 2015-01-02 | 2021-01-01 | No | 4 | M | Direct |
| 26,000 | 2015-01-02 | 2021-01-01 | No | 4 | M | Direct |
| 21,680 | 2015-01-02 | 2021-01-01 | No | 4 | M | Direct |
Footnotes
- Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 3, 2015.
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 3, 2015.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.
- Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 2, 2020.
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 2, 2020.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $51.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) of this Form 4.
Billionaire Hedge Funds
